ArticleWorld journal of gastroenterology2012
Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature.PloS one · 2013Pooled it
- The Role ofMedicina (Kaunas, Lithuania) · 2020Trial
- The interplay between COX-2, chemotherapeutic drugs, and chemoresistance in colon cancer.Scientific reports · 2025Article
- Expression of cyclooxygenase-2 (COX-2) in colorectal carcinoma in an indigenous African population of Kano, Nigeria.Ecancermedicalscience · 2024Article
- Survivin expression is associated with lymph node metastasis and short survival in patients with colorectal adenocarcinoma.International journal of clinical and experimental pathology · 2024Article
- Cyclooxygenase-2 immunohistochemical expression is associated with worse prognosis in breast cancer: Retrospective study and literature review.Saudi medical journal · 2022Review
- Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer.International journal of clinical and experimental pathology · 2020Article
- Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer.International journal of molecular sciences · 2019Review
- Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.Analytical cellular pathology (Amsterdam) · 2019Article
- Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.Saudi medical journal · 2018Article
- New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.Journal of mammary gland biology and neoplasia · 2015Review
- c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence.BMC cancer · 2015Article
- Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.Molecular cancer · 2015Article
- Expression of COX-2 and HER-2 in colorectal cancer and their correlation.World journal of gastroenterology · 2015Article
- Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
- Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma.Pakistan journal of medical sciencesArticle
- CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage.Pakistan journal of medical sciencesArticle
- Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo correlate cyclooxygenase-2 (COX-2) expression profile with clinical and pathological variables to assess their prognostic/predictive value in colorectal carcinoma (CRC).
methodsArchival tumor samples were analyzed using immunohistochemistry for COX-2 expression in 94 patients with CRC. Patients were diagnosed and treated at the Departments of Surgery and Oncology, King Abdulaziz University Hospital, Saudi Arabia.
resultsFifty-six percent of the tumors showed positive cytoplasmic COX-2 expression, whereas 44% of cases were completely COX-2-negative. There were no significant correlations between COX-2 expression and sex, age, grade or tumor location. However, COX-2 expression revealed a significant correlation with tumor stage (P = 0.01) and distant metastasis (P = 0.02), and a borderline association with lymph node involvement (P = 0.07). Tumors with high COX-2 expression showed a higher recurrence rate than tumors with no expression (P < 0.009). In univariate Kaplan-Meier survival analysis, there was a significant (P = 0.026) difference in disease-free survival between COX-2-positive and negative tumors in favor of the latter. COX-2 expression did not significantly predict disease-specific survival, which was much shorter for COX-2-positive tumors. In multivariate (COX) models, COX-2 did not appear among the independent predictors of disease-free survival or disease-specific survival.
conclusionCOX-2 expression seems to provide useful prognostic information in CRC, while predicting the patients at high risk for recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.